NIH's RADx Initiative Spends $92.6M on Diagnostic Tech, Primarily with Quidel Corp

Contract Overview

Contract Amount: $92,645,362 ($92.6M)

Contractor: Quidel Corp

Awarding Agency: Department of Health and Human Services

Start Date: 2020-07-30

End Date: 2025-04-30

Contract Duration: 1,735 days

Daily Burn Rate: $53.4K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: THE NATIONAL INSTITUTE OF HEALTH (NIH) LAUNCHED THE RAPID ACCELERATION OF DIAGNOSTICS (RADS) INITIATIVE TO SPEED INNOVATION IN THE DEVELOPMENT, COMMERCIALIZATION, AND IMPLEMENTATION OF TECHNOLOGIES TO SIGNIFICANTLY INCREASE THE U.S. TESTING CAPACIT

Place of Performance

Location: SAN DIEGO, SAN DIEGO County, CALIFORNIA, 92121

State: California Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $92.6 million to QUIDEL CORP for work described as: THE NATIONAL INSTITUTE OF HEALTH (NIH) LAUNCHED THE RAPID ACCELERATION OF DIAGNOSTICS (RADS) INITIATIVE TO SPEED INNOVATION IN THE DEVELOPMENT, COMMERCIALIZATION, AND IMPLEMENTATION OF TECHNOLOGIES TO SIGNIFICANTLY INCREASE THE U.S. TESTING CAPACIT Key points: 1. Significant investment in diagnostic innovation through the RADx initiative. 2. Quidel Corp. is a major recipient, highlighting potential vendor concentration. 3. Contract awarded without full and open competition raises questions about price discovery. 4. Focus on accelerating diagnostic technology development and implementation.

Value Assessment

Rating: fair

The contract value of $92.6 million for a definitive contract is substantial. Without specific benchmarks for similar RADx-related procurements or detailed cost breakdowns, assessing its value for money is challenging. The fixed-price nature provides some cost certainty.

Cost Per Unit: N/A

Competition Analysis

Competition Level: limited

The contract was not competed fully and openly, indicating a limited competition approach. This method may have been chosen for speed or specific vendor capabilities, but it potentially limits price discovery and could lead to higher costs compared to a fully competitive process.

Taxpayer Impact: Taxpayer funds are being directed towards critical health initiatives, but the lack of full competition warrants scrutiny to ensure optimal use of resources.

Public Impact

Accelerates development of crucial diagnostic tools, potentially improving public health response. Supports innovation in a key area of healthcare technology. Concentration of funds with a single vendor could limit broader market participation.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Limited competition may result in suboptimal pricing.
Vendor concentration risk.

Positive Signals

Supports critical health initiative (RADx).
Focus on innovation and implementation.

Sector Analysis

The contract falls within the Analytical Laboratory Instrument Manufacturing sector, a critical component of healthcare infrastructure. Spending benchmarks for similar rapid innovation initiatives are scarce, making direct comparisons difficult. The $92.6M award is significant for a single contract in this specialized area.

Small Business Impact

The data does not indicate any specific provisions or awards made to small businesses under this contract. The focus appears to be on larger, established entities capable of rapid development and commercialization.

Oversight & Accountability

Oversight is crucial given the limited competition and significant funding. The NIH's RADx program structure likely includes internal review mechanisms, but external auditing of cost-effectiveness and vendor performance would enhance accountability.

Related Government Programs

Analytical Laboratory Instrument Manufacturing
Department of Health and Human Services Contracting
National Institutes of Health Programs

Risk Flags

Potential for inflated costs due to limited competition.
Over-reliance on a single vendor.
Lack of transparency in vendor selection process.
Uncertainty regarding long-term cost-effectiveness.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $92.6 million to QUIDEL CORP. THE NATIONAL INSTITUTE OF HEALTH (NIH) LAUNCHED THE RAPID ACCELERATION OF DIAGNOSTICS (RADS) INITIATIVE TO SPEED INNOVATION IN THE DEVELOPMENT, COMMERCIALIZATION, AND IMPLEMENTATION OF TECHNOLOGIES TO SIGNIFICANTLY INCREASE THE U.S. TESTING CAPACIT

Who is the contractor on this award?

The obligated recipient is QUIDEL CORP.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $92.6 million.

What is the period of performance?

Start: 2020-07-30. End: 2025-04-30.

What was the justification for limiting competition for this significant contract within the RADx initiative?

The justification for limited competition likely stems from the RADx initiative's urgent need to accelerate diagnostic development and deployment. Specific vendors may have been selected based on pre-existing expertise, proprietary technology, or the ability to rapidly scale production, aligning with the program's time-sensitive goals.

How does Quidel Corp.'s role in this contract align with the broader goals of the RADx initiative regarding market diversity?

Quidel Corp.'s significant role suggests they are a key partner in achieving RADx objectives. However, it raises questions about whether this concentration limits opportunities for other innovative small or medium-sized businesses to contribute, potentially impacting the diversity of diagnostic solutions developed.

What mechanisms are in place to ensure the long-term effectiveness and cost-efficiency of the diagnostic technologies funded through this contract?

Effectiveness is likely monitored through performance metrics tied to technology development milestones and implementation success. Cost-efficiency may be assessed through post-award reviews and comparisons with market alternatives as technologies mature. The fixed-price contract provides some cost control, but ongoing evaluation is essential.

Industry Classification

NAICS: Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Analytical Laboratory Instrument Manufacturing

Product/Service Code: MEDICAL SERVICES › LABORATORY TESTING SERVICES

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Ortho-Clinical Diagnostics, Inc.

Address: 9975 SUMMERS RIDGE RD, SAN DIEGO, CA, 92121

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $92,645,362

Exercised Options: $92,645,362

Current Obligation: $92,645,362

Actual Outlays: $90,339,712

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline